Clinical Validation of the Intermediate-risk Non–muscle-invasive Bladder Cancer Scoring System and Substratification Model Proposed by the International Bladder Cancer Group: A Multicenter Young Academic Urologists Urothelial Working Group Collaboration
Francesco Soria(Medical University of Vienna), Paolo Gontero(Fondazione Ricerca Molinette), Daniele Dutto, Stefano Mancon(Humanitas University), David D‘Andrea(Medical University of Vienna), Ekaterina Laukhtina(Comprehensive Cancer Center Vienna), Alberto Briganti(University College London Hospitals NHS Foundation Trust), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Benjamin Pradère, Diego M. Carrión(Hospital Universitario de Torrejón), Fabrizio Di Maida(University of Florence), Simone Albisinni(University of Rome Tor Vergata), Mario de Angelis(IRCCS Ospedale San Raffaele), Matteo Rosazza, Jeremy Yuen‐Chun Teoh(Chinese University of Hong Kong), Renate Pichler(Innsbruck Medical University), Shahrokh F. Shariat(Universitätszahnklinik Wien), Rodolfo Hurle(IRCCS Humanitas Research Hospital), Marco Moschini(Vita-Salute San Raffaele University), Simone Livoti, Andrea Mari(Azienda Ospedaliero-Universitaria Careggi), Francesco Del Giudice(Sapienza University of Rome), G. Fertitta, Fulvia Colucci, Laura S. Mertens(Oncode Institute), Giulia Casale, Wojciech Krajewski(Wroclaw Medical University)
Cited by 32
Related Papers
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
|European Urology|2023|618
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)
|World Journal of Urology|2016|471
Urothelial Carcinoma of the Bladder and the Upper Tract: Disparate Twins
|The Journal of Urology|2012|359